Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
1 finding from 1 review
Hypoxaemia · patients undergoing surgery requiring anaesthesia
1 finding from 1 review
no estimate extracted
235 participants
GRADE not reported
Changes to patient care · patients undergoing surgery requiring anaesthesia
1 finding from 1 review
no estimate extracted
21037 participants
GRADE not reported
Complications · patients undergoing surgery requiring anaesthesia
1 finding from 1 review
no estimate extracted
20802 participants
GRADE not reported
In‐hospital mortality · patients undergoing surgery requiring anaesthesia
1 finding from 1 review
no estimate extracted
22021 participants
GRADE not reported
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event Pain as · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Time needed until improvement ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with refractory glaucoma
1 finding from 1 review
Mean change in the mean deviation in study eyes change from baseline 12 months postintervention · adults with refractory glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean number of antiglaucoma medications at 1‐year · adults with refractory glaucoma
1 finding from 1 review
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Mean change in quality of life scores 12 months postintervention · adults with refractory glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain control · adults with refractory glaucoma
1 finding from 1 review